Legal & General Group PLC Bridge Bio Pharma, Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 339,490 shares of BBIO stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

339,490

Previous 159,573 112.75%

Holding current value

$22.5 Million

Previous $6.89 Million 155.92%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$42.78 - $54.29 $7.7 Million - $9.77 Million	179,917 Added 112.75%	339,490 $17.6 Million
Q2 2025 Aug 12, 2025	BUY	$30.14 - $45.12 $714,800 - $1.07 Million	23,716 Added 17.46%	159,573 $6.89 Million
Q1 2025 May 15, 2025	BUY	$28.12 - $37.59 $51,150 - $68,376	1,819 Added 1.36%	135,857 $4.7 Million
Q4 2024 Feb 13, 2025	BUY	$22.35 - $29.5 $82,829 - $109,327	3,706 Added 2.84%	134,038 $3.68 Million
Q3 2024 Feb 28, 2025	SELL	$23.91 - $31.3 $342,558 - $448,435	-14,327 Reduced 10.69%	119,711 $3.05 Million

Q3 2024 Nov 14, 2024	SELL	$23.91 - $31.3 $920,798 - $1.21 Million	-38,511 Reduced 22.81%	130,332 $3.32 Million
Q2 2024 May 29, 2025	BUY	$23.0 - $31.04 $28,405 - $38,334	1,235 Added 0.79%	158,222 $4.01 Million
Q2 2024 Aug 14, 2024	BUY	$23.0 - $31.04 $272,688 - $368,010	11,856 Added 7.55%	168,843 $4.28 Million
Q1 2024 May 29, 2025	BUY	$27.35 - $40.45 $577,905 - $854,708	21,130 Added 15.55%	156,987 $4.85 Million
Q1 2024 May 14, 2024	BUY	$27.35 - $40.45 $1.64 Million - $2.43 Million	60,022 Added 61.9%	156,987 $4.85 Million
Q4 2023 May 29, 2025	SELL	$24.02 - $43.89 $934,185 - $1.71 Million	-38,892 Reduced 28.63%	96,965 $3.91 Million
Q4 2023 Feb 15, 2024	BUY	$24.02 - $43.89 $101,796 - $186,005	4,238 Added 4.57%	96,965 $3.91 Million
Q3 2023 Nov 14, 2023	SELL	$16.89 - $35.01 $12,802 - $26,537	-758 Reduced 0.81%	92,727 $2.45 Million
Q2 2023 Aug 14, 2023	BUY	$13.29 - $18.01 $92,073 - $124,773	6,928 Added 8.0%	93,485 $1.61 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $24,944 - $64,535	3,479 Added 4.19%	86,557 $1.44 Million
Q4 2022 Feb 14, 2023	BUY	$6.74 - $11.52 $7,070 - $12,084	1,049 Added 1.28%	83,078 $633,000
Q3 2022 Nov 14, 2022	SELL	$7.94 - $12.36 $208,393 - $324,400	-26,246 Reduced 24.24%	82,029 $816,000
Q2 2022 Aug 22, 2022	BUY	$5.21 - $12.14 $122,492 - $285,423	23,511 Added 27.74%	108,275 $983,000
Q1 2022 May 16, 2022	SELL	$7.34 - $17.16 $7,464 - $17,451	-1,017 Reduced 1.19%	84,764 $861,000
Q4 2021 Feb 14, 2022	BUY	$11.38 - $53.41 $68,177 - $319,979	5,991 Added 7.51%	85,781 $1.43 Million
Q3 2021 Nov 15, 2021	BUY	$46.87 - $64.24 $615,871 - $844,113	13,140 Added 19.71%	79,790 $3.74 Million
Q2 2021 Aug 12, 2021	BUY	$46.47 - $63.93 $332,167 - $456,971	7,148 Added 12.01%	66,650 $4.06 Million
Q1 2021 May 17, 2021	BUY	$55.47 - $72.35 $569,676 - $743,034	10,270 Added 20.86%	59,502 $3.67 Million
Q4 2020 Feb 12, 2021	BUY	$38.38 - $71.11 $293,875 - $544,489	7,657 Added 18.42%	49,232 $3.5 Million
Q3 2020 Nov 13, 2020	BUY	$27.2 - $42.19 $637,404 - $988,680	23,434 Added 129.18%	41,575 $1.56 Million
Q2 2020 Aug 14, 2020	BUY	$22.22 - $35.69 $147,985 - $237,695	6,660 Added 58.01%	18,141 $590,000
Q1 2020 May 14, 2020	BUY	$16.11 - $36.23 $113,349 - $254,914	7,036 Added 158.29%	11,481 $310,000
Q4 2019 Feb 13, 2020	BUY	$17.96 - $46.63 $13,128 - $34,086	731 Added 19.68%	4,445 $156,000
Q3 2019 Nov 13, 2019	BUY	$20.13 - $32.38 $73,635 - $118,446	3,658 Added 6532.14%	3,714 $80,000
Q2 2019 Aug 14, 2019	BUY	$26.97 - $27.55 $1,510 - $1,542	56 New	56 $2,000

Others Institutions Holding BBIO

# of Institutions

449

Shares Held

185M

Call Options Held

11.3M

Put Options Held

1.82M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $9.84B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Bridge Bio Pharma, Inc. Transaction History